Commit Biologics
Every major immunotherapy modality — checkpoint inhibitors, CAR-Ts, T-cell engagers — works through T cells. Commit Biologics is betting that the complement system, the immune system’s oldest and most potent killing machinery, is the next effector mechanism to be weaponized for autoimmune disease and cancer.
Europe-Based
Preclinical
Bispecific
Antibody
Autoimmune
Why Highlight Commit Biologics Now?
Commit just appointed serial biotech founder Thomas Andresen as CEO, closed a €21.5M seed round led by Novo Holdings, and is preparing to nominate its first two clinical development candidates later in 2026 — backed by NHP proof-of-concept data showing deep B-cell depletion without cytokine release, using a mechanism that no other company in the clinic is pursuing.
Company Snapshot
Focus: Bispecific complement engagers (BiCE™) for B-cell depletion in autoimmune disease and cancer
Problem: Existing B-cell depletion therapies (anti-CD20s, CAR-Ts, T-cell engagers) rely on cytokine-dependent effector mechanisms — limited by incomplete tissue depletion, CRS risk, and T-cell exhaustion
Approach: Bispecific single-domain antibodies that recruit C1q and the complement cascade directly at target cells; modular plug-and-play design compatible with existing antibody formats; 30+ years Aarhus University complement biology expertise
Lead Programs: Two clinical development candidates targeting B-cell antigens in autoimmune disease and oncology; nomination expected 2026
Backing: €21.5M seed from Novo Holdings, Bioqube Ventures, and Korys; runway into late 2026; Innobooster Grant from Innovation Fund Denmark
Leadership: Thomas L. F. Montgomery Andresen, PhD (CEO) — serial biotech founder, ex-CEO T-Cypher Bio, co-founder Torque Therapeutics (acquired by Repertoire Immune Medicines), 220+ papers, 50+ patents
Company Overview
Commit Biologics is developing a new class of immune engagers that recruit the complement cascade — the innate immune system’s fastest-acting killing mechanism — to deplete specific cell populations in autoimmune disease and cancer. The company’s BiCE™ (Bispecific Complement Engaging) platform pairs single-domain antibodies against complement protein C1q with a target-binding arm, supercharging conventional antibodies to drive potent complement-dependent cytotoxicity without triggering systemic cytokine release.
Spun out of Aarhus University in Denmark in 2021, Commit builds on three decades of academic complement research. A November 2025 NHP study demonstrated rapid, deep B-cell depletion after a single dose, with sustained depletion beyond four weeks and no adverse clinical observations — establishing complement engagement as a viable, cytokine-independent alternative to T-cell-directed therapies for B-cell-mediated diseases.
Pipeline Overview
BiCE™ Candidate 1 — Anti-B-cell complement engager in autoimmune disease
Lead complement engager targeting a B-cell antigen for autoimmune indications. NHP proof-of-concept demonstrated deep, sustained B-cell depletion without cytokine release. Development candidate nomination expected 2026.
BiCE™ Candidate 2 — Anti-tumor complement engager in oncology
Second BiCE™ candidate targeting a tumor-associated antigen. Preclinical data have shown superior complement-mediated cell killing versus clinically approved T-cell engagers and ADCC-enhanced antibodies. Candidate nomination expected 2026.
BiCE™ Platform — Modular complement engager pipeline
Broader pipeline of BiCE™ candidates across multiple tumor-associated antigens and immune cell targets. Modular plug-and-play design enables rapid candidate generation by swapping the target-binding arm while retaining the C1q-engaging domain.
Competitive Landscape
| Company | Approach | Stage | Differentiator |
|---|---|---|---|
| Commit Biologics | BiCE™ complement engager (C1q-recruiting bispecific) | Preclinical | Only company recruiting complement via C1q; NHP proof-of-concept; no CRS signal; 30yr academic foundation |
| Sanofi / Dren Bio | Bispecific myeloid cell engager (CD20-directed phagocytosis) | Phase 1 | $600M upfront acquisition; myeloid-driven B-cell depletion; different innate effector mechanism |
| Xencor | Plamotamab (CD20×CD3 T-cell engager) | Phase 1b | T-cell-directed; RA proof-of-concept; Fc-engineered bispecific; cytokine risk inherent to mechanism |
| Kyverna Therapeutics | CD19 CAR-T (miv-cel) for autoimmune disease | BLA filing | First autoimmune CAR-T nearing approval (SPS); autologous manufacturing complexity; deep but costly depletion |
| Roche / Genentech | Obinutuzumab (Type II anti-CD20 mAb) | Approved | Enhanced ADCC/direct cell death; approved in lupus nephritis; gold-standard comparator but incomplete tissue depletion |
| Rituximab (biosimilars) | Type I anti-CD20 mAb (ADCC/CDC) | Generic | 20+ year track record; cheap/accessible; but ~30% anti-drug antibodies, incomplete B-cell depletion |
Key insight: The B-cell depletion space is exploding — Sanofi paid $600M upfront for Dren Bio’s myeloid engager, and Kyverna is filing for the first autoimmune CAR-T approval — but no one else is recruiting the complement cascade directly via C1q engagement. Commit occupies genuinely uncrowded mechanistic territory in a market where big pharma is aggressively acquiring next-generation depletion technologies.
Market Context
The global autoimmune disease drug market is valued at approximately $126 billion in 2025 and growing at 7.5% CAGR. B-cell depletion therapies specifically are at an inflection point: Sanofi’s $600M acquisition of Dren Bio’s myeloid engager, Kyverna’s imminent BLA filing for autoimmune CAR-T, and Roche’s expanding obinutuzumab label collectively signal that next-generation B-cell depletion is where big pharma sees the largest return. A complement-based approach that avoids the manufacturing complexity of CAR-T and the cytokine risk of T-cell engagers could slot in as the off-the-shelf, scalable backbone of next-generation autoimmune treatment.
Potential Impact
The unlock
The complement system is the innate immune system’s most potent and rapid effector mechanism — it evolved long before T cells — yet it has never been deliberately recruited as the primary therapeutic mechanism for cell depletion. If BiCE™ demonstrates clinical activity with a clean cytokine profile, it establishes complement engagement as a new therapeutic modality alongside ADCC, T-cell engagement, and CAR-T. That opens a modality-level platform opportunity across any indication where targeted cell depletion is the goal.
For investors
Commit is pre-clinical candidate nomination with €21.5M at Novo Holdings valuation — a modest entry point for a differentiated platform play in a market where Sanofi just paid $600M upfront for a single bispecific B-cell depleter. The binary events are clear: clinical candidate nomination (2026), IND-enabling studies, and first-in-human dosing. If the complement engagement mechanism translates from NHP to patients without CRS, the Series A story writes itself. The risk is mechanism-specific: does C1q recruitment drive sufficient complement activation at clinically achievable doses?
For pharma BD
Any large pharma building a next-generation autoimmune franchise should be evaluating Commit now — before clinical candidate data shifts the negotiating leverage. The BiCE™ platform’s modular design means it can be plugged into existing antibody portfolios as an enhancement layer, making a co-development or platform licensing deal structurally attractive at this stage.
Commit Biologics
| Founded | 2021 |
| Location | Aarhus, Denmark |
| Stage | Preclinical |
| Status | Private |
| Total Funding | €21.5M (Seed) |
| Lead Investors | Novo Holdings, Bioqube Ventures, Korys |
Leadership
Key Technology
Bispecific antibodies combining a C1q-binding single-domain antibody with a target-binding arm. Recruits the classical complement pathway directly at the cell surface, driving complement-dependent cytotoxicity independent of T cells or cytokine release.
Plug-and-play architecture allows rapid candidate generation by swapping the target arm while retaining the validated C1q-engaging domain. Compatible with existing antibody formats and combinable with other mechanisms of action.
Company profile generated by Biotech Voyager · Data sourced from HOUSTON Intelligence Platform, company disclosures, and public filings
